REVEAL GENOMICS held its annual Cycle Meeting in Barcelona, bringing together the company’s leadership team and European staff to review progress, align on strategic priorities, and define the next phase of growth.
The meeting convened the full C-Line leadership team, including Patricia Villagrasa, Chief Executive Officer and Co-Founder; Ángeles Sebastián, Chief Operating Officer; Joel S. Parker, Chief Scientific Officer and Co-Founder; Laia Paré, Chief Technology Officer; and Adriana Herrera, Chief Marketing Officer, alongside team members from across Europe. Aleix Prat, Co-Founder and President of the Board of Directors, also participated, contributing to discussions on the company’s long-term vision and continued leadership in precision oncology.
A central focus of the meeting was reinforcing REVEAL GENOMICS’ strategic roadmap, with particular emphasis on its international expansion and growing presence in the United States. As the company continues to scale its operations, it is prioritizing the strengthening of commercial capabilities, the expansion of strategic partnerships, and the optimization of its go-to-market approach to accelerate adoption across key markets. The integration and alignment of its European headquarters with its expanding U.S. team is a key priority to support global growth and execution.
The session enabled cross-functional collaboration across scientific, clinical, technological, and commercial areas, with updates shared on ongoing initiatives and progress in advancing the company’s genomic platforms. These efforts are aimed at improving treatment decision-making and delivering clinically actionable insights in oncology.
Strategic discussions also addressed upcoming milestones, including expansion into new clinical indications, deepening collaborations with leading academic institutions, and strengthening partnerships with pharmaceutical companies. Together, these initiatives position REVEAL GENOMICS to further extend the clinical impact and global reach of its technologies.
Reflecting this momentum, the company continues to invest in talent across both Europe and the United States, reinforcing its scientific, clinical, and operational capabilities to support sustained growth.
Hosted at the company’s headquarters in Barcelona, the meeting reinforced internal alignment while highlighting REVEAL GENOMICS’ evolution into a transatlantic organization. Building on this, the company is planning future Cycle Meetings that will bring together both its European and U.S. teams, further strengthening collaboration and cohesion across its international structure.